StreetInsider.com News Articles

Form D Medicenna Therapeutics

Mon, 06 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26736103.html

Form D Medicenna Therapeutics

Mon, 06 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26736103.html

Form D Medicenna Therapeutics

Mon, 06 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26736103.html

H.C. Wainwright Reiterates Buy Rating on Medicenna Therapeutics (MDNA)

Thu, 02 Jul 2026 06:44:42 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $2.50 price target on Medicenna Therapeutics (NASDAQ: MDNA).

The analyst commented: "On June 26, 2026, Medicenna reported FY2026 results (fiscal year ended March 31, 2026) and provided a corporate update. The Phase 1/2 ABILITY-1 study evaluating MDNA11, a long-acting beta-enhanced IL-2 superagonist (no IL-2Rα binding), is on track to complete enrollment in 3Q26, prioritizing select advanced tumor types (cutaneous melanoma, endometrial cancer, and MSI-H/dMMR and MSS/TMB-H cancers) with a focus on 2L/3L post-anti-PD-1 settings. Enrollment is also underway for its Phase 1b NEO-CYT study evaluating MDNA11 in neoadjuvant melanoma with interim

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna raises CDN$4.44 million in public offering of units

Thu, 28 May 2026 09:10:51 -0400

Medicenna Therapeutics Corp. (TSX: MDNA) completed a public offering of 8,880,000 units at CDN$0.50 per unit, raising approximately CDN$4.44 million in gross proceeds before expenses.

Each unit consists of one common share and one-half of a common share purchase warrant. The warrants allow holders to purchase additional shares at CDN$0.65 each for three years following the closing date.

Bloom Burton Securities Inc. served as the sole agent for the offering under an agency agreement dated May 21, 2026. The company issued 450,100 compensation warrants to the agent, exercisable at CDN$0.50 per share for two years.

The offering was conducted under a prospectus supplement

Medicenna raises CDN$4.44 million in public offering of units

Thu, 28 May 2026 09:10:51 -0400

Medicenna Therapeutics Corp. (TSX: MDNA) completed a public offering of 8,880,000 units at CDN$0.50 per unit, raising approximately CDN$4.44 million in gross proceeds before expenses.

Each unit consists of one common share and one-half of a common share purchase warrant. The warrants allow holders to purchase additional shares at CDN$0.65 each for three years following the closing date.

Bloom Burton Securities Inc. served as the sole agent for the offering under an agency agreement dated May 21, 2026. The company issued 450,100 compensation warrants to the agent, exercisable at CDN$0.50 per share for two years.

The offering was conducted under a prospectus supplement

Medicenna raises CDN$4.44 million in public offering of units

Thu, 28 May 2026 09:10:51 -0400

Medicenna Therapeutics Corp. (TSX: MDNA) completed a public offering of 8,880,000 units at CDN$0.50 per unit, raising approximately CDN$4.44 million in gross proceeds before expenses.

Each unit consists of one common share and one-half of a common share purchase warrant. The warrants allow holders to purchase additional shares at CDN$0.65 each for three years following the closing date.

Bloom Burton Securities Inc. served as the sole agent for the offering under an agency agreement dated May 21, 2026. The company issued 450,100 compensation warrants to the agent, exercisable at CDN$0.50 per share for two years.

The offering was conducted under a prospectus supplement

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Thu, 28 May 2026 09:10:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Thu, 28 May 2026 09:10:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Thu, 28 May 2026 09:10:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Thu, 28 May 2026 09:10:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Thu, 28 May 2026 09:10:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Thu, 28 May 2026 09:10:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

Fri, 22 May 2026 07:00:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

Fri, 22 May 2026 07:00:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

Fri, 22 May 2026 07:00:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

Fri, 22 May 2026 07:00:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

Fri, 22 May 2026 07:00:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

Fri, 22 May 2026 07:00:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of units of the Company (“Units”), it has filed a prospectus supplement (the “Prospectus Supplement”) to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the ”Base Shelf Prospectus”) with the